Merit Medical Systems has concluded the acquisition of a dialysis catheter product portfolio and the BioSentry Tract Sealant System Biopsy product from AngioDynamics for a cash consideration of $100m.
Under the deal, Merit Medical purchased DuraMax, DuraFlow, Trio-CT, Evenmore Schon X and Vaxel Plus haemodialysis catheter brands from AngioDynamics.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The BioSentrybiopsy tract sealant system helps reduce the incidence of biopsy-related pneumothorax (collapsed lung).
The combined portfolio of products generated sales of approximately $32m for AngioDynamics during the fiscal year 2023.
Proceeds from the transaction will allow AngioDynamics to clear its existing debt and make strategic investments in growth and profitability.
AngioDynamics president and CEO Jim Clemmer said: “This is another significant step in our transformation and finding an excellent partner to take on these leading dialysis and biopsy assets allows our team to more tightly align around the company’s core strategic platforms.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRecently, Merit Medical also purchased the Surfacer Inside-Out access catheter system from Bluegrass Vascular Technologies for $32.5m in cash.
The Surfacer is a unique device developed to facilitate repeated right-sided catheter placement for central venous access in patients with venous obstructions.
Merit chairman and CEO Fred Lampropoulos said: “These acquisitions strengthen our position in the dialysis and biopsy markets and expand the foundation of our growing speciality dialysis device offering, which includes WRAPSODY Cell-Impermeable Endoprosthesis, HeROGraft and the Surfacer System devices.
“Many dialysis patients rely on these solutions to receive vital therapies. Combining this broad portfolio of interventional solutions within Merit will allow us to leverage our physician relationships and commercial infrastructure to serve more patients in the multi-billion dialysis market.”
